先知生技榮獲2025年國家生技研究園區DEMO DAY決賽「最佳投資獎(Investment Award)」
2025年7月22日於中研院生醫轉譯研究中心舉辦的2025年國家生技研究園區DEMO DAY決賽中，先知生物科技以其創新的免疫治療平台獲得「最佳投資獎(Investment Award)」肯定，展現台灣在生技產業創新上的強勁實力。
聚焦CD11b的創新免疫療法
先知生技專注於從免疫反應上游切入，開發以CD11b為核心靶點的獨特免疫療法平台。其旗艦產品ASD141是一款創新的先天免疫檢查點抑制劑，目前已於台灣開始臨床一期試驗。ASD141可與Mac-1受體上的CD11b亞基結合，有效阻斷TLT-1的結合，進而增強腫瘤抑制作用。 在臨床前的人源化動物模型中，ASD141已證明其與Keytruda相比擁有極佳的抑癌效果。更值得注意的是，ASD141與現有熱門療法（抗PD-1、抗PD-L1、CTLA-4）聯合使用時，可以進一步提升腫瘤治療成效。
產品多元，療效創新
除腫瘤免疫療法外，先知生技亦開發出自體免疫疾病療法ASD-001。在小鼠潰瘍性結腸炎發炎模型中，ASD-001的表現優於目前市場主流用藥Remicade，展現成為新世代精準、安全治療選項的潛力。
奪得「最佳投資獎(Investment Award)」肯定
本次國家生技研究園區DEMO DAY賽事由全球產業專家組成評審團，評分重點包含技術創新、市場潛力、團隊管理與簡報表現。先知生技在激烈競爭中脫穎而出，榮獲「投資獎」肯定，展現其研發實力和未來成長潛力。
代表台灣生技創新精神
先知生技以突破性的免疫治療平台不僅獲得專業評審的高度肯定，也展現台灣生技產業在全球的創新競爭力。隨著臨床與產品開發持續推進，先知生技勢必將帶來更多突破性的療法，造福更多癌症及自體免疫疾病患者。
Ascendo Biotech Receives “Investment Award” at the 2025 National Biotechnology Research Park DEMO DAY Finals
On July 22, 2025, at the Biomedical Translation Research Center of Academia Sinica, Ascendo Biotech was honored with the “Investment Award” at the 2025 National Biotechnology Research Park (NBRP) DEMO DAY Finals. The recognition highlights the company’s innovative immunotherapy platform and underscores Taiwan’s strength in global biotech innovation.
Pioneering Immunotherapy Targeting CD11b
Ascendo Biotech is advancing a novel immunotherapy platform focused on upstream immune modulation, with CD11b as its key target. Its lead candidate, ASD141, is a first-in-class innate immune checkpoint inhibitor currently in Phase I clinical trials in Taiwan. ASD141 binds to the CD11b subunit of the Mac-1 receptor, effectively blocking TLT-1 interaction and enhancing anti-tumor immune responses.
In preclinical humanized models, ASD141 demonstrated tumor suppression comparable to Keytruda. Importantly, it showed synergistic effects when combined with other checkpoint inhibitors, including anti-PD-1, anti-PD-L1, and CTLA-4 antibodies—amplifying its therapeutic potential in combination regimens.
Diversified Pipeline with Breakthrough Potential
In addition to oncology, Ascendo Biotech is developing ASD-001, a novel treatment for autoimmune diseases. In a murine model of inflammatory bowel disease (IBD), ASD-001 outperformed Remicade, a market-leading therapy, indicating its potential as a next-generation, precise, and safer therapeutic option.
Recognized for Investment Value
A panel of global industry experts evaluated DEMO DAY participants on innovation, market potential, team strength, and presentation. Ascendo Biotech stood out among strong competitors to win the “Investment Award”, reflecting confidence in its scientific foundation and future growth trajectory.
Demonstrating Taiwan’s Biotech Innovation Power
Ascendo Biotech’s groundbreaking immunotherapy platform not only garnered professional acclaim but also exemplified Taiwan’s rising influence in global biotech innovation. As clinical and pipeline development progresses, the company is poised to deliver transformative therapies to patients with cancer and autoimmune diseases worldwide.
2025 DEMO DAY決賽「最佳投資獎(Investment Award)」